NCT05923177 2025-04-09
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase 1 Completed
Clinical Trials
8 trialsNCT03270007 2020-10-28
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
Peking University
Phase 4 Unknown
NCT01314833 2020-05-19
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
Fudan University
Phase 3 Completed
NCT04127019 2020-02-26
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
Fudan University
Phase 3 Completed
NCT01033162 2019-11-18
Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care
University of Wisconsin, Madison
Phase NA Completed
NCT01049425 2019-08-14
planB
West German Study Group
Phase 3 Completed
NCT00527449 2010-01-15
ETCat01
Klinikum Weissenfels
Phase 2 Completed
NCT00793377 2008-11-19
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
GBG Forschungs GmbH
Phase 3 Completed